No advantage of dexamethasone over prednisolone for the outcome of standard- and intermediate-risk childhood acute lymphoblastic leukemia in the Tokyo Children's Cancer Study Group L95-14 protocol

Journal of Clinical Oncology

Volumn 23, Issue 27, 2005, Pages 6489-6498

  Igarashi, Shunji ^a   Manabe, Atsushi ^b   Ohara, Akira ^b   Kumagai, Masaaki ^b   Saito, Tomohiro ^b   Okimoto, Yuri ^b   Kamijo, Takehiko ^b   Isoyama, Keiichi ^b   Kajiwara, Michiko ^b   Sotomatsu, Manabu ^b   Sugita, Ken Ichi ^b   Sugita, Kanji ^b   Maeda, Miho ^b   Yabe, Hiromasa ^b   Kinoshita, Akitoshi ^b   Kaneko, Takashi ^b   Hayashi, Yasuhide ^b   Ikuta, Kouichiro ^b   Hanada, Ryohji ^b   Tsuchida, Masahiro ^b  

^a NARITA RED CROSS HOSPITAL   (Japan)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ASPARAGINASE; CYCLOPHOSPHAMIDE; CYTARABINE; DEXAMETHASONE; DOXORUBICIN; HYDROCORTISONE; MERCAPTOPURINE; METHOTREXATE; PREDNISONE; VINCRISTINE; PREDNISOLONE;

ACUTE LYMPHOBLASTIC LEUKEMIA; AGITATION; ARTICLE; BONE NECROSIS; BRAIN HEMORRHAGE; CANCER REGISTRY; CANCER RELAPSE; CANCER RISK; CANCER SURVIVAL; CHILD; CHILDHOOD CANCER; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG SUBSTITUTION; ERYTHROPHAGOCYTOSIS; HUMAN; MAJOR CLINICAL STUDY; MOYAMOYA DISEASE; MULTIPLE CYCLE TREATMENT; MYCOSIS; PANCREATITIS; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SEPSIS; SIDE EFFECT; STROKE; TREATMENT FAILURE; TREATMENT OUTCOME; ACUTE LYMPHOCYTIC LEUKEMIA; COMPARATIVE STUDY; DOSE RESPONSE; DRUG ADMINISTRATION; FEMALE; FOLLOW UP; HOSPITALIZATION; JAPAN; MALE; MORTALITY; PRESCHOOL CHILD; PROBABILITY; PROSPECTIVE STUDY; RECURRENT DISEASE; REFERENCE VALUE; RISK ASSESSMENT; SENSITIVITY AND SPECIFICITY;

CHILD; CHILD, PRESCHOOL; DEXAMETHASONE; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; FEMALE; FOLLOW-UP STUDIES; HUMANS; JAPAN; LEUKEMIA, LYMPHOCYTIC, ACUTE, L1; MALE; PREDNISOLONE; PROBABILITY; PROSPECTIVE STUDIES; RECURRENCE; REFERENCE VALUES; RISK ASSESSMENT; SENSITIVITY AND SPECIFICITY; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME;

EID: 27244436741     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2005.01.982     Document Type: Article

References (19)

1. Balis FM, Lester CM, Chrousos GP, et al: Differences in cerebrospinal fluid penetration of corticosteroids: Possible relationship to the prevention of meningeal leukemia. J Clin Oncol 5:202-207, 1987
2. Jones B, Freeman AI, Shuster JJ, et al: Lower incidence of meningeal leukemia when prednisone is replaced by dexamethasone in the treatment of acute lymphocytic leukemia. Med Pediatr Oncol 19:269-275, 1991
3. Veerman AJ, Hahlen K, Kamps WA, et al: High cure rate with a moderately intensive treatment regimen in non-high-risk childhood acute lymphoblastic leukemia: Results of protocol ALL VI from the Dutch Childhood Leukemia Study Group. J Clin Oncol 14:911-918, 1996
4. Silverman LB, Gelber RD, Dalton VK, et al: Improved outcome for children with acute lymphoblastic leukemia: Results of Dana-Farber Consortium Protocol 91-01. Blood 97:1211-1218, 2001
5. Ito C, Evans WE, McNinch L, et al: Comparative cytotoxicity of dexamethasone and prednisolone in childhood acute lymphoblastic leukemia. J Clin Oncol 14:2370-2376, 1996
6. Gaynon PS, Lustig RH: The use of glucocorticoids in acute lymphoblastic leukemia of childhood: Molecular, cellular, and clinical considerations. J Pediatr Hematol Oncol 17:1-12, 1995
7. Bostrom BC, Sensel MR, Sather HN, et al: Dexamethasone versus prednisone and daily oral versus weekly intravenous mercaptopurine for patients with standard-risk acute lymphoblastic leukemia: A report from the Children's Cancer Group. Blood 101:3809-3817, 2003
8. Mitchell CD, Kinsey S, Vora AJ, et al: MRC ALL97/99: A randomized comparison of dexamethasone versus prednisolone and thioguanine versus mercaptopurine in the treatment of childhood acute lymphoblastic leukemia. Blood 100: 586, 2002 (abstr 586)
9. Hurwitz CA, Silverman LB, Schorin MA, et al: Substituting dexamethasone for prednisone complicates remission induction in children with acute lymphoblastic leukemia. Cancer 88:1964-1969, 2000
10. Belgaumi AF, Al-Bakrah M, Al-Mahr M, et al: Dexamethasone-associated toxicity during induction chemotherapy for childhood acute lymphoblastic leukemia is augmented by concurrent use of daunomycin. Cancer 97:2898-2903, 2003
11. Mattano LA Jr, Sather HN, Trigg ME, et al: Osteonecrosis as a complication of treating acute lymphoblastic leukemia in children: A report from the Children's Cancer Group. J Clin Oncol 18:3262-3272, 2000
12. Arico M, Boccalatte MF, Silvestri D, et al: Osteonecrosis: An emerging complication of intensive chemotherapy for childhood acute lymphoblastic leukemia. Haematologica 88:747-753, 2003
13. Dropcho EJ, Soong SJ: Steroid-induced weakness in patients with primary brain tumors. Neurology 41:1235-1239, 1991
14. Waber DP, Carpentieri SC, Klar N, et al: Cognitive sequelae in children treated for acute lymphoblastic leukemia with dexamethasone or prednisone. J Pediatr Hematol Oncol 22:206-213, 2000
15. Toyoda Y, Manabe A, Masahiro T, et al: Six months of maintenance chemotherapy after intensified treatment for acute lymphoblastic leukemia of childhood. J Clin Oncol 18:1508-1516, 2000
16. Kaplan E, Meier P: Nonparametric estimation from incomplete observations. J Am Stat Assoc 53:457-481, 1958
17. Reiter A, Schrappe M, Ludwig WD, et al: Chemotherapy in 998 unselected childhood acute lymphoblastic leukemia patients: Results and conclusions of the multicenter trial ALL-BFM 86. Blood 84:3122-3133, 1994
18. Lange BJ, Bostrom BC, Cherlow JM, et al: Double-delayed intensification improves event-free survival for children with intermediate-risk acute lymphoblastic leukemia: A report from the Children's Cancer Group. Blood 99:825-833, 2002
19. Hann I, Vora A, Richards S, et al: Benefit of intensified treatment for all children with acute lymphoblastic leukaemia: Results from MRC UKALL XI and MRC ALL97 randomised trials-UK Medical Research Council's Working Party on Childhood Leukaemia. Leukemia 14: 356-363, 2000